3. Overall survival (OS) and 1‐year survival (1yOS) for platinum combination versus non‐platinum therapy.
| Author, year | Inclusion criteria (age and PS) |
n (elderly) |
N‐based therapy | P‐based combination | HR (95% CI) | P value | ||
| Median OS in months (95% CI) | 1yOS | Median OS in months (95% CI) | 1yOS | |||||
| Zukin 2013 | ≥ 18 yo and PS 2 | 74 | 5.3 (NR) | NR | 9.9 (NR) | NR | 0.49 (0.34‐0.70) | 0.006 |
| Quoix 2011b | ≥ 70 yo | 451 | 6.2 (5.3‐7.3) | 25.4% (19.9‐31.3) | 10.3 (8.3‐12.6) | 44.5% (37.9‐50.9) | 0.64 (0.52‐0.78) | < 0.0001 |
| Abe 2011 | ≥ 70 yo | 233 | 14.8 (11.9‐24.1) | 58.2% (48.3‐66.9) | 13.3 (10.8‐19.4) | 54.5% (44.8‐63.3) | 1.18 (0.83‐1.69) | 0.82 |
| Lou 2010 | ≥ 70 yo | 68 | 9.9 (NR) | 31% (NR) | 9.8 (NR) | 32% (NR) | NR | > 0.05 |
| Chen 2008 | ≥ 70 yo | 65 | 12 (NR) | 50.9% | 11.3 (NR) | 47.2% | 0.65 (0.31‐1.36) | 0.25 |
| Tsukada 2007 | ≥ 70 yo | 112 | 17 (NR) | 66.6% | 10.7 (NR) | 45.2% | 0.69 (0.45‐1.06) | 0.09 |
| Zhang 2006 | ≥ 65 yo | 96 | 8 (NR) | 36.7% (NR) | CisP arm: 9 (NR) | 38.2% (NR) | NR | < 0.05 |
| CarP arm: 10 (NR) | 43.8% (NR) | NR | < 0.05 | |||||
| Lilenbaum 2005 | ≥ 18 yo | 152 | 5.8 (3.8‐9.3) | 31% (22‐43) | 8.0 (5.7‐11) | 35% (26‐48) | 0.84 (0.61‐1.16) | 0.29 |
| Georgoulias 2004 | ≤ 75 yo | 70 | 6.9 (NR) | 38.2% (NR) | 8.0 (NR) | 37.4% (NR) | 0.88 (0.52‐1.48) | 0.63 |
| Boni 2012 | ≥ 70 yo | 101 | NR | NR | NR | NR | 0.76 (0.52‐1.16) | 0.21 |
| Flotten 2012 | No upper age limit | 74* | 4.6 (NR) | 18% | 8.0 (NR) | 28% | 0.59 (0.36‐0.95) | 0.03 |
| Kubota 2008 | NR | 118 | 13.2 (NR) | 56.8% | 13.3 (NR) | 53.6% | 0.99 (0.65‐1.52) | 0.97 |
| Georgoulias 2005 | 18 to 75 yo | 82 | 9.3 (NR) | 33.1% | 8.8 (NR) | 34.3% | 1.05 (0.64‐1.72) | 0.86 |
| Laack 2004 | 18 to 75 yo | 43 | 30.5 (19.4‐61.9) weeks | 30% (10.2‐53.0) | 32.4 (8.4‐80.3) weeks | 34.1% (16.6‐52.5) | 0.87 (0.42‐1.80) | 0.71 |
| Georgoulias 2001 | ≤ 75 yo | 71 | 6.7 (NR) | 33.3% | 7.1 (NR) | 34.3% | 1.08 (0.67‐1.74) | 0.76 |
1yOS: 1‐year survival rate; CarP arm: carboplatin and paclitaxel arm; CI: confidence interval; CispP arm: cisplatin and paclitaxel arm; HR: hazard ratio; NR: not reported; PS: performance status; yo: years old.